(Q46509671)

English

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

scientific article published on 6 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

cholangiocarcinoma

0 references

immunohistochemistry

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas von Deimling

12

object named as

Andreas von Deimling

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

15

object named as

David Capper

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

Arianeb Mehrabi

9

object named as

Arianeb Mehrabi

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

14

object named as

Wilko Weichert

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

author name string

Benjamin Goeppert

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Lena Frauenschuh

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Marcus Renner

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Stephanie Roessler

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Albrecht Stenzinger

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Frederick Klauschen

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Arne Warth

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Monika Nadja Vogel

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Mohammadreza Hafezi

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Katja Boehmer

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Peter Schirmacher

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

publication date

6 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

Modern Pathology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

27

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

1028-1034

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

https://scigraph.springernature.com/pub.10.1038/modpathol.2013.206

0 references

Clinical diagnosis and staging of cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

BRAF(E600) in benign and malignant human tumours

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Targeting BRAF for patients with melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Brainstem ganglioglioma successfully treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

BRAF inhibition in refractory hairy-cell leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Targeting the BRAF V600E mutation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

The V599E BRAF mutation is uncommon in biliary tract cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

21 January 2018

Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

7 January 2021

based on heuristic

inferred from DOI database lookup

BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2013.206

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2013.206

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/24309328

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46509671&oldid=2115344519"